Compare Organon & Co. Common Stock (OGN) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Taskus Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Taskus Inc trades at $8.1 (market cap $750.00M). The key difference: Organon & Co. Common Stock is far larger — about 4.8× Taskus Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Taskus Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Taskus Inc for 35 Days on average.
| OGN | TASK | |
|---|---|---|
Market Cap | $3.62B | $750.00M |
Volume | 2,892,999 | 195,383 |
Sector | Health | Technology |
52-Week High | $13.81 | $14.30 |
52-Week Low | $5.70 | $4.57 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $11.04B | $1.12B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
TaskUs (TASK) trades at $8.14, up 1.88% with bullish technical signals from moving averages. The company shows strong fundamentals with revenue growth to $1.18B in 2025 and net income margin expanding to 8.75%. Valuation metrics appear attractive with P/E of 7.05 and P/S of 0.62. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.28 expected, driven by AI services growth offsetting declines in other segments.
The outlook remains positive with analyst consensus price target of $9.33 representing 15% upside potential. Key opportunities include AI services expansion growing 26% annually, while risks involve margin compression from higher labor costs and client concentration. Institutional ownership increased with Dimensional Fund Advisors raising stake by 12.8% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
